Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Enliven Therapeutics (ELVN) Enterprise Value (2023 - 2026)

Enliven Therapeutics has reported Enterprise Value over the past 8 years, most recently at -$452.4 million for Q1 2026.

  • Quarterly results put Enterprise Value at -$452.4 million for Q1 2026, down 56.24% from a year ago — trailing twelve months through Mar 2026 was -$452.4 million (down 56.24% YoY), and the annual figure for FY2025 was -$462.6 million, down 272.57%.
  • Enterprise Value reached -$452.4 million in Q1 2026 per ELVN's latest filing, up from -$462.6 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$75.5 million in Q4 2022 and bottomed at -$490.5 million in Q2 2025.
  • Median Enterprise Value over the past 5 years was -$253.1 million (2023), compared with a mean of -$232.5 million.
  • The largest annual shift saw Enterprise Value surged 65.12% in 2024 before it tumbled 406.06% in 2025.
  • Over 5 years, Enterprise Value stood at -$75.5 million in 2022, then plummeted by 235.14% to -$253.1 million in 2023, then surged by 50.95% to -$124.2 million in 2024, then crashed by 272.57% to -$462.6 million in 2025, then increased by 2.21% to -$452.4 million in 2026.
  • Business Quant data shows Enterprise Value for ELVN at -$452.4 million in Q1 2026, -$462.6 million in Q4 2025, and -$101.7 million in Q3 2025.